上海谊众药业股份有限公司（以下简称"上海谊众"）发布的2025年业绩快报显示，报告期内，公司实现 营收3.17亿元，同比增长82.72%；实现归母净利润6413.20万元，同比增长819.42%。上海谊众表示，公 司核心产品注射用紫杉醇聚合物胶束于2025年正式纳入《国家医保药品目录》，在市场准入与用药人数 上大幅提高，带动了公司全年营收与利润增长。 "政策红利的持续释放，是行业企业业绩增长的重要助推因素。医保目录动态调整机制显著缩短了新药 从获批到覆盖的周期，近八成创新药能在两年内进入医保，加速了商业化落地。"无锡医库软件科技有 限公司董事长涂宏钢说。 行业整体向好发展，也不断吸引资本目光。开源证券研报显示，2025年全球医疗健康产业投融资额达 638.82亿美元，同比增长10.13%。从国内来看，医疗健康领域一级市场融资回暖更为明显，2025年全年 投融资总额达737.77亿元，同比增长39.05%；中国新药申报IND数量2025年达2175个，同比增长8.8%。 "亮眼成绩单虽令人振奋，但创新药企仍需警惕研发不确定性与市场竞争加剧的挑战，持续修炼内功仍 是企业长久生存与发展之道。"涂宏钢表示，随着商保目 ...

证券代码：688321 证券简称：微芯生物 公告编号：2026-014 深圳微芯生物科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司2025年 年度报告为准，提请投资者注意投资风险。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 1、报告期内的主要经营情况及财务状况 报告期内，公司2025年年度营业收入为90,953.78万元；利润总额为5,084.33万元；归属于上市公司股东 的净利润为5,107.57万元；归属于上市公司股东的扣除非经常性损益的净利润为3,835.62万元；每股收益 为0.1252元。 2、影响经营业绩的主要因素 一、2025年度主要财务数据和指标 单位：万元 ■ 注：1.本报告期初数同法定披露的上年年末数。 2.以上财务数据及指标以公司报表数据填列，但未经审计，最终结果以公司2025年年度报告为准。 3.以上增减变动幅度数据如有 ...

（原标题：微芯生物(688321.SH)：2025年度净利润为5107.57万元） 格隆汇2月26日丨微芯生物(688321.SH)公布2025年度业绩快报，报告期内，公司2025年年度营业收入为 90,953.78万元；利润总额为5,084.33万元；归属于上市公司股东的净利润为5,107.57万元；归属于上市公 司股东的扣除非经常性损益的净利润为3,835.62万元；每股收益为0.1252元。 本报告期内，公司产品西格列他钠依托"糖肝共管"独特的临床价值，叠加自营、战略合作商与新零售渠 道发力，商业化成效显著，销售收入同比增长122%左右；公司产品西达本胺的临床价值获得国家医保 局的支持与市场的认可，新增适应症弥漫大B细胞淋巴瘤于2025年1月纳入《国家医保目录》，并于同 年12月纳入最新版《国家医保目录》常规乙类管理，在医保连续降价以及2025年第四季度库存补差的影 响下，销售收入同比增长16%左右。综上，公司营业收入相应增长，归属母公司所有者的净利润实现扭 亏为盈。 ...

本报告期内，公司产品西格列他钠依托"糖肝共管"独特的临床价值，叠加自营、战略合作商与新零售渠 道发力，商业化成效显著，销售收入同比增长122%左右；公司产品西达本胺的临床价值获得国家医保 局的支持与市场的认可，新增适应症弥漫大B细胞淋巴瘤于2025年1月纳入《国家医保目录》，并于同 年12月纳入最新版《国家医保目录》常规乙类管理，在医保连续降价以及2025年第四季度库存补差的影 响下，销售收入同比增长16%左右。综上，公司营业收入相应增长，归属母公司所有者的净利润实现扭 亏为盈。 格隆汇2月26日丨微芯生物(688321.SH)公布2025年度业绩快报，报告期内，公司2025年年度营业收入为 90,953.78万元；利润总额为5,084.33万元；归属于上市公司股东的净利润为5,107.57万元；归属于上市公 司股东的扣除非经常性损益的净利润为3,835.62万元；每股收益为0.1252元。 ...

微芯生物公告称，2025年度公司实现营业总收入9.10亿元，同比增长38.24%；利润总额5084.33万元， 上年同期为-9671.19万元；归母净利润5107.57万元，上年同期为-1.15亿元，实现扭亏为盈。产品西格列 他钠销售收入同比增长122%左右，西达本胺销售收入同比增长16%左右。公司表示，上述财务数据为 初步核算数据，未经审计，具体以2025年年度报告为准。 ...

Core Insights - The company is expected to achieve profitability by 2025, with significant breakthroughs in international expansion and promising clinical data for its product, Westoroni, in the pancreatic cancer field [1][2]. Financial Performance - The company's revenue forecast for 2025 is projected at 910 million yuan, representing a year-on-year growth of 38.32% [2]. - The net profit attributable to shareholders is expected to be 53.46 million yuan, marking a turnaround from previous losses [2]. - Key products, including Sigleth sodium, have seen a sales revenue increase of approximately 123% year-on-year, while Sidabamine, despite facing price reductions from insurance, still achieved a 16% growth [2]. Recent Developments - On February 10, 2026, the company announced progress in its international expansion, granting exclusive rights for Sidabamine to Russian pharmaceutical company Nizhpharm in the CIS and Central Asia, which includes an upfront payment of 10 million yuan [3]. - The updated Phase II clinical data for Westoroni in combination chemotherapy shows a 50% objective response rate (ORR) and a median progression-free survival (mPFS) of 9.1 months, supporting further development [3]. Stock Performance - Over the past week (February 5 to 11, 2026), the company's stock price fluctuated between a high of 32.47 yuan and a low of 30.75 yuan, with a total decline of 0.76% [4]. - On February 10, the stock price increased by 1.28%, with a net inflow of 28.19 million yuan from major funds; however, it closed at 31.21 yuan on February 11, down 1.73% for the day [4]. - The financing balance has been increasing, with a recent growth of 5.57% over the past five days [4].

Group 1: Company Performance - Microchip Biotech forecasts a turnaround to profitability in 2025, with projected revenue of 910 million yuan, a year-on-year increase of 38.32% [1] - The net profit attributable to shareholders is expected to reach 53.46 million yuan, a significant improvement from a loss of 115 million yuan in the previous year, marking an increase of 168 million yuan [1] - Revenue growth is primarily driven by the commercialization of core products, with sales of Sigleptin sodium increasing approximately 123% due to its clinical value in "diabetes-liver management" and effective collaboration between self-operated and channel sales [1] - Sales of Sidabamine, despite facing price reductions and inventory adjustments, still achieved a year-on-year growth of 16% after being included in the national medical insurance catalog for a new indication of diffuse large B-cell lymphoma [1] Group 2: Strategic Developments - The company has made a breakthrough in business development by granting exclusive rights for Sidabamine to the Russian pharmaceutical company Nizhpharm for research, registration, and commercialization in 12 CIS and Central Asian countries [2] - Nizhpharm will pay an upfront fee of 10 million yuan and a milestone payment of 10 million yuan upon registration, along with a high double-digit percentage of net sales in the authorized regions [2] - Sidabamine is the world's first subtype-selective HDAC inhibitor, approved for multiple indications in China and Japan, and is currently undergoing Phase III clinical trials for additional indications [2] Group 3: Clinical Research Updates - Xioroni has updated data on pancreatic cancer, showing potential in treatment through both single-agent exploration in the U.S. and combination chemotherapy in China [3] - In a Phase II study for first-line treatment of pancreatic ductal adenocarcinoma, Xioroni combined with AG chemotherapy demonstrated a breakthrough efficacy potential, achieving an objective response rate (ORR) of 50% [3] - The median progression-free survival (mPFS) is reported at 9.1 months, with approximately half of the patients still on treatment after a median follow-up of 9.6 months [3] - Xioroni shows promising synergy with targeted drugs like RAS inhibitors in various mouse models, indicating enhanced tumor suppression effects when combined [3] - The U.S. Phase I dose-escalation trial for Xioroni is nearing completion, with the company actively advancing its overseas development and collaboration efforts [3]

截至2026年1月27日收盘，微芯生物(688321)报收于33.6元，下跌2.3%，换手率4.03%，成交量16.43万 手，成交额5.47亿元。 当日关注点 公司公告汇总 2025年年度业绩预告公告 深圳微芯生物科技股份有限公司预计2025年年度实现营业收入91,008.00万元左右，同比增长38.32%左 右；归属于上市公司股东的净利润5,346.00万元左右，同比增加16,803.06万元左右，实现扭亏为盈；扣 除非经常性损益后的净利润为3,814.00万元左右。业绩增长主要得益于西格列他钠销售收入同比增长 123%，西达本胺新增适应症纳入国家医保目录带动销售增长。本次业绩预告未经注册会计师审计。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月27日主力资金净流出7124.75万元，占总成交额13.02%。 来自公司公告汇总：微芯生物预计2025年净利润扭亏为盈，归母净利润达5,346.00万元左右，主要 受益于西格列他钠销售增长及西达本胺新适应症纳入医保。 交易信息汇总 资金流向 1月27日主力资金 ...

Market Overview - The A-share market experienced a decline, with the Shanghai Composite Index closing at 4132.61, down 0.09%, and the Shenzhen Component Index down 0.85% at 14316.64 [5][8] - The overall market saw a trading volume of 32,806.44 billion, an increase of 1,625.37 billion from the previous trading day, indicating active trading despite the market's downturn [9][11] Economic Insights - The People's Bank of China conducted a 7-day reverse repurchase operation of 150.5 billion at an interest rate of 1.40%, resulting in a net withdrawal of 7.8 billion for the day [21] - By the end of 2025, the total number of new energy vehicles in China is expected to reach 43.97 million, accounting for 12.01% of the total vehicle population [22][23] - Domestic travel by residents is projected to increase by 907 million trips in 2025, with total travel expenditure reaching 6.3 trillion, a year-on-year increase of 9.5% [24][25] Industry Dynamics - Tianjin has adjusted its housing provident fund loan policies, raising the maximum loan limits for first and second homes to 1.2 million and 1 million respectively [26][27] - The National Development and Reform Commission has issued guidelines to promote the sustainable development of intercity railways, emphasizing planning, operational optimization, and risk management [32][34][35] Company Updates - Micron Biologics (688321.SH) expects a revenue of 910 million for 2025, a year-on-year increase of approximately 38.32%, with a projected net profit of 53 million, marking a turnaround from losses [36][37] - Miaokelan (600882.SH) plans to recognize a fair value change loss related to an acquisition fund, which may significantly impact its net profit for 2025 [38][39] - Six Nations Chemical (600470.SH) anticipates a net loss of 480 million to 410 million for 2025 due to intensified competition and export restrictions [41][42] - Huaxin Co. (600621.SH) expects a net profit increase of approximately 77.48% for 2025, driven by growth in investment and brokerage business revenues [43] - Hunan Gold (002155.SZ) forecasts a net profit increase of 50% to 90% for 2025, attributed to rising sales prices of gold, antimony, and tungsten products [44][45]

Core Viewpoint - Microchip Biotech (688321.SH) forecasts a net profit of approximately 53.46 million yuan for the year 2025, marking an increase of about 168.03 million yuan compared to the previous year, thus achieving a turnaround from loss to profit [1] Group 1: Financial Performance - The company expects a net profit attributable to shareholders of approximately 53.46 million yuan for 2025, which represents a year-on-year increase of about 168.03 million yuan [1] - The company's revenue is projected to grow significantly, driven by the commercial success of its products [1] Group 2: Product Performance - The product Siglecatinib has shown remarkable commercial effectiveness, with sales revenue increasing by approximately 123% year-on-year due to its unique clinical value in "diabetes liver management" and the expansion of self-operated, strategic partnerships, and new retail channels [1] - The product Sidabenamine has gained recognition in the market and support from the National Healthcare Security Administration, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Directory in January 2025, contributing to a year-on-year sales revenue growth of about 16% [1]